Allman T Rollins

Allman T Rollins

Auto-generated profile, based on publicly available information

Allman T Rollins

Vanderbilt Transplant Center, Nashville, TN, US; Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, US

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2021 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
TETracey M Ellimuttil
Tracey M Ellimuttil
KHKimberly Harrison
Kimberly Harrison
ARAllman T Rollins
Allman T Rollins
IFIrene D Feurer
Irene D Feurer
SRScott A Rega
Scott A Rega
JMJonathan N Menachem
Jonathan N Menachem
Background: In the non-transplant population, hyperlipidaemia has shifted from targeting LDL goals to statin intensity-based treatment. It is unknown whether this strategy is also beneficial in cardiac transplantation. Methods: This single-centre retrospective study evaluated the effect of statin use and intensity on time to cardiac allograft vasculopathy (CAV) after cardiac transplantation. Kaplan–Meier and Cox proportional hazards regression survival methods were used to assess the association of statin intensity and median post-transplant LDL on CAV-free survival. Results: The study involved 143 adults (71% men, average follow-up of 25 ± 14 months) who underwent transplant between 2013 and 2017. Mean CAV-free survival was 47.5 months (95% CI [43.1–51.8]), with 29 patients having CAV grade 1 or greater. Median LDL was not associated with time to CAV (p=0.790). CAV-free survival did not differ between intensity groups (p=0.435). Conclusion: Given the non-statistically significant difference in time to CAV with higher intensity statins, the data suggest that advancing moderate- or high-intensity statin after cardiac transplantation may not provide additional long-term clinical benefit. Trial registration: Not applicable.